Literature DB >> 7687001

[Effect of mistletoe lectin therapy on serum level of defined serum proteins (acute phase proteins) in tumor patients].

J Beuth1, H J Gabius, M K Steuer, J Geisel, M Steuer, H L Ko, G Pulverer.   

Abstract

The influence of galactoside-specific mistletoe lectin (ML-1) administration on defined acute phase reactants in the serum of cancer patients (mammary carcinoma, n = 4; larynx carcinoma, n = 11; TNM-stages II to IV; after appropriate surgery, chemotherapy, radiation) was studied. Regular subcutaneous injections of the optimal doses of ML-1 (1 mg/kg body weight, twice a week) yielded statistically significant increases of certain acute phase reactants (C-reactive protein, haptoglobin, coeruloplasmin, C3-complement, albumin, immunoglobulin IgM) after four weeks of treatment. However, serum concentrations of transferrin, C4-complement and the immunoglobulins IgG and IgA were found within the biological range (means +/- 2 s). The increase of acute phase reactants after administration of ML-1 correlates positively with the activity of lymphatic cells (e.g. expression of IL-2 and HLA-DR receptors) in FACS (fluorescence-activated cell sorter) staining experiments and indicates the immunoreactive potency of this substance which may be speculated to be cytokine-induced.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687001

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  4 in total

1.  Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro.

Authors:  G Stein; P A Berg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

2.  Oncopharmacological Perspectives of a Plant Lectin (Viscum album Agglutinin-I): Overview of Recent Results from In vitro Experiments and In vivo Animal Models, and Their Possible Relevance for Clinical Applications.

Authors:  Tibor Hajtó; Katarina Hostanska; Timea Berki; László Pálinkás; Ferenc Boldizsár; Péter Németh
Journal:  Evid Based Complement Alternat Med       Date:  2005-01-28       Impact factor: 2.629

Review 3.  Preclinical and clinical effects of mistletoe against breast cancer.

Authors:  Mohsen Marvibaigi; Eko Supriyanto; Neda Amini; Fadzilah Adibah Abdul Majid; Saravana Kumar Jaganathan
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

4.  Adjuvant Therapy Using Mistletoe Containing Drugs Boosts the T-Cell-Mediated Killing of Glioma Cells and Prolongs the Survival of Glioma Bearing Mice.

Authors:  Sonja Schötterl; Stephan M Huber; Hans Lentzen; Michel Mittelbronn; Ulrike Naumann
Journal:  Evid Based Complement Alternat Med       Date:  2018-08-27       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.